Clinical trial
The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer
NCT00452556 is registered in ClinicalTrials.gov with Nova Scotia Cancer Centre as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study: A Phase II Study of Chemo - Hormonal Therapy and Radiation in High Risk Prostate Cancer
- Lead sponsor
- Nova Scotia Cancer Centre
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 31, 2007
- Completion date
- February 28, 2017
- Enrollment
- 86 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.